ArticleJournal of translational medicine2026
An epithelial cell fate-driven predictive model for liver metastasis risk in primary colorectal cancer through single-cell and multi-omics integration.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is the third most prevalent form of cancer worldwide, with colorectal cancer liver metastases (CRLM) representing a principal cause of CRC-related mortality. However, a lack of molecular subgroups based on the differentiation states of diverse cell types in CRLM poses a significant barrier to progress in precision therapy.
methodsWe integrated single-cell RNA sequencing (scRNA-seq, GSE178318) of paired CRLM tissues to define an epithelial cell fate gene signature. To evaluate the intrinsic "malignant seed" potential, this signature was projected onto a large-scale primary reference cohort (TCGA-COAD/READ, N = 433) using consensus clustering to establish the Malignant Development Signature of CRLM (MDSCRLM). Comprehensive multi-omics analyses-encompassing somatic mutations, copy number variations, tumor mutational burden (TMB), and ATAC-seq chromatin accessibility (N = 81)-alongside immune microenvironment deconvolutions and proteomic data integration were performed. The clinical relevance of the MDSCRLM model was externally validated using immunohistochemistry in an independent clinical cohort of 45 patients. Furthermore, the biological function of HSPA1A, a core marker, was experimentally verified through in vitro assays and in vivo metastasis models.
resultsThe MDSCRLM system discriminates three distinctmetastatic risk trajectories: Cluster 1-Aggressive-Metastasis-Enhanced CRLM (AMECRLM), Cluster 2-Cell Cycle-Active CRLM (CCACRLM), and Cluster 3-Growth-Inhibited CRLM (GICRLM). Survival analyses in the primary reference cohort validated the biological plausibility and prognostic impact of this model, revealing that GICRLM is associated with the most favorable prognosis while AMECRLM confers the poorest outcome. Our findings delineate distinct patterns of cellular heterogeneity, genomic instability (TP53 mutations), and gene expression across CRLM developmental stages. Prognostic validation in the clinical cohort and functional validation demonstrating that HSPA1A knockout attenuates tumor invasion and metastasis robustly supported the robustness of the MDSCRLM risk stratification.
conclusionsWe established a novel, clinically relevant CRLM risk stratification model with strong diagnostic and prognostic potential. By identifying pre-existing malignant features and stage-specific therapeutic vulnerabilities within the primary tumor, this model bridges the gap between biological discovery and precision medicine in advanced colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.